— Know what they know.
Not Investment Advice

ARYX OTC

ARYx Therapeutics, Inc.
1W: +0.0% 1M: +0.0% 3M: +0.0% YTD: +0.0% 1Y: +0.0% 3Y: +25.0% 5Y: -72.2%
$0.00
Last traded 2026-08-11 — delisted
OTC · Healthcare · Drug Manufacturers - Specialty & Generic · $16731 mcap · 33M float · 0.0055% daily turnover

Cash Flow Trends

Operating Cash Flow
-$35M +22.7% ▲
Capital Expenditures
$141K +78.1% ▲
4Y CAGR: -56.3%
Free Cash Flow
-$35M +23.4% ▲
Dividends Paid
$0 +0.0% ▲
Buybacks
$92K +0.0% ▲
Net Change in Cash
-$29M -46.8% ▼

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2005FY2006FY2007FY2008FY2009
— Operating Activities —
Net Income-$28M-$27M-$28M-$31M-$33M
Depreciation & Amort.$982K$920K$1M$1M$1M
Stock-Based Comp.$0$0$0$0$2M
Change in Working Capital$4M$21M-$2M-$18M-$5M
Other Non-Cash Items$421K$738K$774K$2M$439K
Operating Cash Flow-$22M-$4M-$28M-$45M-$35M
— Investing Activities —
Capital Expenditures-$4M-$962K-$499K-$644K-$141K
Acquisitions (Net)$0$0$0$0$0
Investment Purchases-$23M-$69M-$21M-$17M-$11M
Investment Sales$37M$52M$45M$15M$20M
Other Investing$0$190K-$150K-$300K$200K
Investing Cash Flow$10M-$19M$23M-$2M$8M
— Financing Activities —
Net Debt Issuance$11M-$1M-$3M$8M-$3M
Stock Repurchased$0$0$0$0-$92K
Dividends Paid$0$0$0$0$0
Other Financing$0$0$0$0$0
Financing Cash Flow$11M$29M$41M$28M-$2M
Net Change in Cash-$2M$6M$37M-$19M-$29M
Cash End of Period$12M$19M$55M$36M$7M
Free Cash Flow-$26M-$5M-$28M-$46M-$35M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms